Quiroga J A, Bosch O, Gonzalez R, Marriott E, Castillo I, Bartolome J, Carreño V
Department of Gastroenterology, Fundación Jiménez Díaz, Madrid, Spain.
Gastroenterology. 1992 Oct;103(4):1285-9. doi: 10.1016/0016-5085(92)91517-8.
Testing for immunoglobulin (Ig) M antibody to hepatitis C virus (anti-HCV) as a predictive factor of therapeutic response to recombinant interferon alfa (rIFN-alpha) in chronic hepatitis C was evaluated in 122 patients with IgG anti-HCV. IgM anti-HCV was present in the pretreatment sample of 88% of patients who responded to treatment, including 20 of 21 (95%) long-term responders and 24 of 29 (83%) responders who had relapses after cessation of therapy. In contrast, IgM anti-HCV was present in only 23 of 39 (59%) nonresponders and 22 of 33 (66%) untreated controls (P less than 0.05). The number of cases with detectable IgM anti-HCV tended to decrease in responder patients, which was more evident for complete responders (42%) than for responders who relapsed (72%). During follow-up, the antibody became undetectable in the majority of long-term responders (28% were still IgM anti-HCV positive) but remained detectable in 69% of responders who relapsed (P less than 0.05). No special changes were noted in nonresponder or control patients. Thus, testing for IgM anti-HCV may help to identify a subset of patients who will benefit from rIFN-alpha therapy in chronic hepatitis C.
在122例抗丙型肝炎病毒IgG（抗-HCV）阳性的患者中，评估了丙型肝炎病毒免疫球蛋白（Ig）M抗体（抗-HCV）检测作为慢性丙型肝炎患者对重组干扰素α（rIFN-α）治疗反应预测因子的作用。88%治疗有效的患者治疗前样本中存在抗-HCV IgM，其中包括21例长期有效者中的20例（95%）以及治疗停止后复发的29例有效者中的24例（83%）。相比之下，39例无反应者中仅有23例（59%）以及33例未治疗的对照者中有22例（66%）存在抗-HCV IgM（P<0.05）。治疗有效的患者中可检测到抗-HCV IgM的病例数趋于减少，完全有效者（42%）比复发的有效者（72%）更明显。随访期间，大多数长期有效者中该抗体变得不可检测（28%仍为抗-HCV IgM阳性），但69%复发的有效者中该抗体仍可检测到（P<0.05）。无反应者或对照患者未观察到特殊变化。因此，抗-HCV IgM检测可能有助于识别慢性丙型肝炎中可从rIFN-α治疗中获益的患者亚组。
